Discount Agreements for Vilanterol and Fluticasone Furoate
Titre original de l'avis
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Vilanterol und Fluticasonfuroat, ATC R03AK10
Score d'opportunité
Pourquoi ce score ?
Opportunité
40 / 100
Complexité
30 / 100
Facteurs de risque
The open-house model is not subject to public procurement law. Legal remedies are through social courts, not procuremen...
No guaranteed minimum volume or value; the contract is non-exclusive and may be superseded by other rebate contracts.
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Apr 2027
- Non-exclusive rebate agreements for pharmaceuticals containing Vilanterol and Fluticasone furoate (ATC R03AK10)
- Open-house model (not a competitive procurement)
Afficher le résumé complet
Non-exclusive open-house rebate agreement for the active substance Vilanterol and Fluticasone furoate (ATC R03AK10) with AOK Bayern. All eligible pharmaceutical companies can join under identical non-negotiable terms. Contract term from 01.05.2025 to 30.04.2027, with possibility of early termination. The procedure is not a public procurement but a permitted open-house model.
Risques
The open-house model is not subject to public procurement law. Legal remedies are through social courts, not procuremen...
No guaranteed minimum volume or value; the contract is non-exclusive and may be superseded by other rebate contracts.
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Eligibility
- Only pharmaceutical companies are eligible as potential contractors.
Administrative
- Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
- Contract and annex must be signed and submitted in paper (two copies) with handwritten signature or electronically with qualified electronic signature.
Les exigences peuvent être incomplètes.
Critères d'attribution
Lot 1
Acheteur
Localisation
München, DEU
Site web
Profil acheteur
Identifiant
DE811695320
Activité
Health
Lots (1)
LOT-0001
Discount Agreements for Vilanterol and Fluticasone Furoate
Open-house model for discount agreements on pharmaceuticals containing Vilanterol and Fluticasone furoate. All interested pharmaceutical companies that meet the eligibility criteria may conclude identical non-exclusive rebate agreements.
Localisation
Durée
Catégorie
Critères d'attribution
Date limite
Détails des critères
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Open house Arzneimittelrabattverträge Vilanterol und Fluticasonfuroat, ATC R03AK10
Description TED originale
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Détails de la procédure
- Date de publication
- 18 Mar 2025
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 178616-2025
Documents (2)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
40 / 100
Complexité
30 / 100
Facteurs de risque
The open-house model is not subject to public procurement law. Legal remedies are through social courts, not procuremen...
No guaranteed minimum volume or value; the contract is non-exclusive and may be superseded by other rebate contracts.
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications